Vivoo, a wellness app offering personalized nutrition and lifestyle advice through at-home urine tests, introduced its new digital Urinary Tract Infection (UTI) test at the Consumer Electronic Show (CES) 2024.
Honored with a CES 2024 Innovation Award, the at-home test provides results in just two minutes. Users simply download the app, urinate on the test strip, and scan it with the app for instant results. If necessary, customers can then consult a doctor through the app to receive a prescription.
Vivoo’s latest UTI test utilizes advanced deep-learning image processing technology to deliver highly accurate results. This innovation is designed to provide gold-standard accuracy, streamline the testing process, eliminate confusion in readings, and digitize the results. Users can conveniently share their results with healthcare providers through the app if immediate treatment is needed.
Urinary tract infections (UTIs) are the most prevalent outpatient infections, affecting 50−60% of adult women over their lifetime, with 150 million people impacted globally each year.
Vivoo’s approach eliminates the administrative struggle of sending samples for lab analysis and the risk of data loss associated with traditional instant tests. Also, the company has recently expanded its test offerings to include vaginal pH tests, addressing the needs of its predominantly female user base, which comprises 65% of its customers.
The UTI test kit will be available to consumers starting in Q2 2024, with options for same-day or next-day delivery through Amazon and other retailers. The Vivoo app will also offer free educational content.
Vivoo’s co-founder and CEO, Miray Tayfun, highlighted the product’s potential to transform UTI diagnosis with convenient at-home testing and a user-friendly app, emphasizing the company’s commitment to democratizing healthcare. Tim Draper, founding partner of Draper Associates, praised the test as a breakthrough in empowering individuals to manage their health more effectively.
The global health market, valued at $80.6 billion in 2022, is projected to grow to over $269.3 billion by 2032, with a CAGR of 12.3%. This news follows Vivoo’s successful launch of their ‘smart toilet’ at CES 2023, which received an honouree award in the digital health category.
The company is supported by prominent investors like Draper Associates and Otsuka Pharmaceuticals and has expanded its reach to over 200,000 users across more than 100 countries, with partnerships and distribution in key global markets including Mexico, South Korea, Qatar, The Netherlands, and Japan.
